ארצות הברית - אנגלית - NLM (National Library of Medicine)

unit dose services - levothyroxine sodium anhydrous (unii: 054i36cpmn) (levothyroxine - unii:q51bo43mg4) - levothyroxine sodium anhydrous 0.088 mg - levothyroxine sodium is used for the following indications: - as replacement or supplemental therapy in congenital or acquired hypothyroidism of any etiology, except transient hypothyroidism during the recovery phase of subacute thyroiditis. specific indications include: primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) hypothyroidism and subclinical hypothyroidism. primary hypothyroidism may result from functional deficiency, primary atrophy, partial or total congenital absence of the thyroid gland, or from the effects of surgery, radiation, or drugs, with or without the presence of goiter. hypothyroidism - in the treatment or prevention of various types of euthyroid goiters (see and ), including thyroid nodules (see and ), subacute or chronic iymphocytic thyroiditis (hashimoto's thyroiditis), multinodular goiter (see and ), and, as an adjunct to surgery and radioiodine therapy in the management of thyrotropin-dependent well-differentiated thyroid cancer.

ארצות הברית - אנגלית - NLM (National Library of Medicine)

cardinal health 107, llc - levothyroxine sodium (unii: 9j765s329g) (levothyroxine - unii:q51bo43mg4) - levothyroxine sodium anhydrous 25 ug - hypothyroidism: levothyroxine sodium tablets are indicated as a replacement therapy in primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) congenital or acquired hypothyroidism. pituitary thyrotropin (thyroid-stimulating hormone, tsh) suppression:  levothyroxine sodium tablets are indicated as an adjunct to surgery and radioiodine therapy in the management of thyrotropin-dependent well-differentiated thyroid cancer. limitations of use: levothyroxine sodium tablets are contraindicated in patients with uncorrected adrenal insufficiency [see warnings and precautions (5.3)] . experience with levothyroxine use in pregnant women, including data from post-marketing studies, have not reported increased rates of major birth defects or miscarriages [see data]. there are risks to the mother and fetus associated with untreated hypothyroidism in pregnancy. since tsh levels may increase during pregnancy, ts

ארצות הברית - אנגלית - NLM (National Library of Medicine)

mylan institutional inc. - levothyroxine sodium (unii: 9j765s329g) (levothyroxine - unii:q51bo43mg4) - levothyroxine sodium anhydrous 88 ug - hypothyroidism: levothyroxine sodium tablets are indicated as a replacement therapy in primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) congenital or acquired hypothyroidism. pituitary thyrotropin (thyroid-stimulating hormone, tsh) suppression:  levothyroxine sodium tablets are indicated as an adjunct to surgery and radioiodine therapy in the management of thyrotropin-dependent well-differentiated thyroid cancer. limitations of use: - levothyroxine sodium tablets are not indicated for suppression of benign thyroid nodules and nontoxic diffuse goiter in iodine-sufficient patients as there are no clinical benefits and overtreatment with levothyroxine sodium tablets may induce hyperthyroidism [see warnings and precautions (5.4)]. - levothyroxine sodium tablets are not indicated for treatment of hypothyroidism during the recovery phase of subacute thyroiditis. levothyroxine sodium tablets are contraindicated in patients with uncorrected adrenal insufficie

ארצות הברית - אנגלית - NLM (National Library of Medicine)

mylan pharmaceuticals inc. - levothyroxine sodium (unii: 9j765s329g) (levothyroxine - unii:q51bo43mg4) - levothyroxine sodium anhydrous 25 ug - hypothyroidism: levothyroxine sodium tablets are indicated in adult and pediatric patients, including neonates, as a replacement therapy in primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) congenital or acquired hypothyroidism. pituitary thyrotropin (thyroid-stimulating hormone, tsh) suppression: levothyroxine sodium tablets are indicated in adult and pediatric patients, including neonates, as an adjunct to surgery and radioiodine therapy in the management of thyrotropin-dependent well-differentiated thyroid cancer . limitations of use: levothyroxine sodium tablets are contraindicated in patients with uncorrected adrenal insufficiency [see warnings and precautions (5.4) ] . the clinical experience, including data from postmarketing studies, in pregnant women treated with oral levothyroxine to maintain euthyroid state have not reported increased rates of major birth defects, miscarriages, or other adverse maternal or fetal outcomes. there are risks to the mother and fetus associated wit

ארצות הברית - אנגלית - NLM (National Library of Medicine)

preferred pharmaceuticals inc. - levothyroxine sodium (unii: 9j765s329g) (levothyroxine - unii:q51bo43mg4) - levothyroxine sodium anhydrous 150 ug - hypothyroidism levothyroxine sodium tablets are indicated as a replacement therapy in primary (thyroidal), secondary (pituitary) and tertiary (hypothalamic) congenital or acquired hypothyroidism. pituitary thyrotropin (thyroid-stimulating hormone, tsh) suppression levothyroxine sodium tablets are indicated as an adjunct to surgery and radioiodine therapy in the management of thyrotropin-dependent well-differentiated thyroid cancer. limitations of use: • levothyroxine sodium tablets are not indicated for suppression of benign thyroid nodules and nontoxic diffuse goiter in iodine-sufficient patients as there are no clinical benefits and overtreatment with levothyroxine sodium tablets may induce hyperthyroidism [see warnings and precautions (5.4)]. • levothyroxine sodium tablets are not indicated for treatment of hypothyroidism during the recovery phase of subacute thyroiditis. levothyroxine sodium tablets is contraindicated in patients with uncorrected adrenal insufficiency [see warnings and precauti

ארצות הברית - אנגלית - NLM (National Library of Medicine)

preferrred pharmaeuticals inc. - levothyroxine sodium (unii: 9j765s329g) (levothyroxine - unii:q51bo43mg4) - levothyroxine sodium anhydrous 137 ug - hypothyroidism levothyroxine sodium tablets are indicated as a replacement therapy in primary (thyroidal), secondary (pituitary) and tertiary (hypothalamic) congenital or acquired hypothyroidism. pituitary thyrotropin (thyroid-stimulating hormone, tsh) suppression levothyroxine sodium tablets are indicated as an adjunct to surgery and radioiodine therapy in the management of thyrotropin-dependent well-differentiated thyroid cancer. limitations of use: • levothyroxine sodium tablets are not indicated for suppression of benign thyroid nodules and nontoxic diffuse goiter in iodine-sufficient patients as there are no clinical benefits and overtreatment with levothyroxine sodium tablets may induce hyperthyroidism [see warnings and precautions (5.4)]. • levothyroxine sodium tablets are not indicated for treatment of hypothyroidism during the recovery phase of subacute thyroiditis. levothyroxine sodium tablets is contraindicated in patients with uncorrected adrenal insufficiency [see warnings and precauti

ארצות הברית - אנגלית - NLM (National Library of Medicine)

st marys medical park pharmacy - levothyroxine sodium (unii: 9j765s329g) (levothyroxine - unii:q51bo43mg4) - levothyroxine sodium anhydrous 0.1 mg - levothyroxine sodium is used for the following indications: hypothyroidism - as replacement or supplemental therapy in congenital or acquired hypothyroidism of any etiology, except transient hypothyroidism during the recovery phase of subacute thyroiditis. specific indications include: primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) hypothyroidism and subclinical hypothyroidism. primary hypothyroidism may result from functional deficiency, primary atrophy, partial or total congenital absence of the thyroid gland, or from the effects of surgery, radiation, or drugs, with or without the presence of goiter. pituitary tsh suppression - in the treatment or prevention of various types of euthyroid goiters (see warnings and precautions ), including thyroid nodules (see warnings and precautions ), subacute or chronic iymphocytic thyroiditis (hashimoto's thyroiditis), multinodular goiter (see warnings and preca

ארצות הברית - אנגלית - NLM (National Library of Medicine)

mylan institutional inc. - levothyroxine sodium (unii: 9j765s329g) (levothyroxine - unii:q51bo43mg4) - levothyroxine sodium anhydrous 25 ug - hypothyroidism: levothyroxine sodium tablets are indicated as a replacement therapy in primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) congenital or acquired hypothyroidism. pituitary thyrotropin (thyroid-stimulating hormone, tsh) suppression:  levothyroxine sodium tablets are indicated as an adjunct to surgery and radioiodine therapy in the management of thyrotropin-dependent well-differentiated thyroid cancer. limitations of use: - levothyroxine sodium tablets are not indicated for suppression of benign thyroid nodules and nontoxic diffuse goiter in iodine-sufficient patients as there are no clinical benefits and overtreatment with levothyroxine sodium tablets may induce hyperthyroidism [see warnings and precautions (5.4)]. - levothyroxine sodium tablets are not indicated for treatment of hypothyroidism during the recovery phase of subacute thyroiditis. levothyroxine sodium tablets are contraindicated in patients with uncorrected adrenal insufficie

אוסטרליה - אנגלית - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - levothyroxine sodium, quantity: 75 microgram - tablet, uncoated - excipient ingredients: light magnesium oxide; sodium stearylfumarate; sodium starch glycollate; microcrystalline cellulose; allura red ac aluminium lake; indigo carmine aluminium lake - levothox is indicated for the management of demonstrated thyroid hormone deficiency.,levothox is also used to suppress thyrotropin (tsh) for the management of tsh-responsive tumours of the thyroid.

אוסטרליה - אנגלית - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - levothyroxine sodium, quantity: 75 microgram - tablet, uncoated - excipient ingredients: sodium starch glycollate; microcrystalline cellulose; sodium stearylfumarate; light magnesium oxide; allura red ac aluminium lake; indigo carmine aluminium lake - levothyroxine intas is indicated for the management of demonstrated thyroid hormone deficiency.,levothyroxine intas is also used to suppress thyrotropin (tsh) for the management of tsh-responsive tumours of the thyroid.